Skip to content

Study · Animal study (in vivo) · 2022

3 results

Platelet Membrane-Encapsulated MSNs Loaded with SS31 Peptide Alleviate Myocardial Ischemia-Reperfusion Injury.

Zhang Z, Chen Z, Yang L, Zhang J, Li Y, Li C, Wang R, Wang X, Huang S, Hu Y, Shi J, Xiao W

Journal of functional biomaterials9 Oct 2022Cited by 12 (Europe PMC)

PMID36278650 (opens in a new tab)PMCIDPMC9624354 (opens in a new tab)DOI10.3390/jfb13040181 (opens in a new tab)PepBankPUB-36278650
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Clinically, antioxidant therapy is a potential strategy for myocardial ischemia-reperfusion injury (MI/RI), a common complication of acute myocardial ischemia. The H-D-Arg-Dmt-Ly-Phe-NH2 (SS31) peptide is shown to have amazing antioxidant properties, but its utilization is limited by the peptide characteristics, such as the destruction by proteases and rapid metabolism. Silica nanoparticles (MSNs) comprise an excellent material for peptide delivery, owing to the protection effect relating to peptides. Moreover, platelet membrane (PLTM) is shown to be advantageous as a coat for nanosystems because of its specific protein composition, such that a PLTM-coated nanosystem has a stealth effect in vivo, able to target injury in the cardiovascular system. Based on this feature, we designed and prepared a novel nanocarrier to target SS31 delivery. This carrier is encapsulated by a platelet membrane and loaded with SS31 peptide into MSNs. The results reveal that this delivery system can target SS31 to the injured cardiovascular site, exert antioxidant function, and alleviate MI/RI.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    A platelet membrane-coated silica nanoparticle delivery system targeted SS31 to the injured cardiovascular site.

    In plain wordsA nanoparticle carrier delivered SS31 to the injured heart and vessel area.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableTargeting of SS31 to the injured cardiovascular site
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results reveal that this delivery system can target SS31 to the injured cardiovascular site, exert antioxidant function, and alleviate MI/RI.
    1 context sentence
    Summary · context
    This carrier is encapsulated by a platelet membrane and loaded with SS31 peptide into MSNs.
  2. 02AnimalAnimal study (in vivo)Mechanism

    The SS31-loaded platelet membrane-coated nanoparticle system exerted antioxidant function at the injury site.

    In plain wordsA nanoparticle carrier delivering SS31 produced antioxidant effects at the injured site.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseAntioxidant function
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results reveal that this delivery system can target SS31 to the injured cardiovascular site, exert antioxidant function, and alleviate MI/RI.
    1 context sentence
    Summary · context
    This carrier is encapsulated by a platelet membrane and loaded with SS31 peptide into MSNs.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    The SS31-loaded platelet membrane-coated nanoparticle system alleviated myocardial ischemia-reperfusion injury.

    In plain wordsA nanoparticle carrier delivering SS31 reduced heart injury after blood flow loss and return.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMyocardial ischemia-reperfusion injury
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results reveal that this delivery system can target SS31 to the injured cardiovascular site, exert antioxidant function, and alleviate MI/RI.
    1 context sentence
    Summary · context
    This carrier is encapsulated by a platelet membrane and loaded with SS31 peptide into MSNs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.